Adalimumab - 180 Life Sciences
Alternative Names: Repurposed anti-TNF therapy - 180 Life SciencesLatest Information Update: 28 Dec 2024
At a glance
- Originator 180 Therapeutics
- Developer 180 Life Sciences; University of Oxford
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Dupuytren's contracture; Frozen shoulder
- No development reported Cognition disorders; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in United Kingdom
- 28 Dec 2023 No recent reports of development identified for phase-I development in Cognition-disorders in United Kingdom
- 07 Aug 2023 180 Life Sciences submits a request to conduct a Type C meeting with the US FDA to seek advice for a phase III trial design and to obtain marketing approval for Dupuytren's contracture